Articles tagged "Immunosuppression"

2016 American Transplant Congress
Differences in Reported Barriers to Immunosuppression Adherence Among a Cohort of Pediatric Renal Transplant Recipients from the United States and Canada.
O. Bignall II,^1,2 A. Pai,² S. Amaral,³ S. Furth,³ N. Bergman,² J. Goebel,⁴ The TAKE-IT Study Investigators, B. Foster.⁵
¹Nephrology and Hypertension, Cincinnati Children's Hospital, Cincinnati, OH; ²Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital, Cincinnati, OH; ³Nephrology, The Children's Hospital of Philadelphia, Philadelphia, PA; ⁴Nephrology, Children's Hospital of Colorado, Aurora, CO; ⁵Nephrology, Montreal Children's Hospital, Montreal, QC, Canada.
Aim: The purpose of this study was to examine differences in reported barriers to immunosuppressant adherence (IA) between a cohort of pediatric renal transplant recipients…
2016 American Transplant Congress
Tool to Assess Risk of Non-Adherence in Renal Transplant Candidates.
T. Kaiser,¹ K. Daley,² L. Dick,² L. Deye,² N. Parrish,² J. Huff,² A. Govil,¹ B. Abu Jawdeh,¹ G. Mogilishetty,¹ R. Alloway,¹ E. Woodle.¹
¹Medicine, University of Cincinnati, Cincinnati; ²Transplant, University of Cincinnati Medical Center, Cincinnati, OH.
Nonadherence (NA) is likely the primary driver of late graft loss and was found to occur in 59% of renal transplant (RTx) patients at our…
2016 American Transplant Congress
Pharmacist Impact on Medication Errors in a Chronic Kidney Transplant Clinic.
K. Covert,¹ C. Mardis,¹ J. Fleming,¹ A. Mardis,¹ H. Meadows,¹ N. Pilch,¹ P. Mohan,² M. Posadas,² M. Salazar,² T. Srinivas,² G. Mour,² D. Taber.¹
¹Pharmacy, The Medical University of South Carolina, Charleston, SC; ²Transplant Nephrology, The Medical University of South Carolina, Charleston, South Carolina.
Medication errors are associated with increased incidence of infection, rejection, and graft loss in kidney transplant recipients. This study aims to assess the impact of…
2016 American Transplant Congress
Prospective Randomized OPEN Trial Designed to Reduce the Incidence of Cytomegalovirus (CMV) Infection in DE NOVO Kidney Transplant Recipients Two-Year Results.
R. Esmeraldo, M. Oliveira, P. Pinheiro, C. Girao, T. Freitas.
Transplant, Hospital Geral de Fortaleza, Fortaleza, CE, Brazil.
Introduction: CMV infection is a frequent complication following organ transplantation, and is associated with inferior long-term patient and graft survival. Here we report the results…
2016 American Transplant Congress
Modification of DC Phenotype and Function via Targeted Porous Silicon Nanoparticles.
S. Stead,¹ S. McInnes,² S. Kireta,³ P. Rose,¹ D. Rojas-Canales,³ S. Jesudason,³ S. Grey,⁴ R. Carroll,³ N. Voelcker,² P. Coates.^1,3
¹School of Medicine, University of Adelaide, Adelaide, Australia; ²Future Industries Institute, University of South Australia, Adelaide, Australia; ³CNARTS, Royal Adelaide Hospital, Adealide, Australia; ⁴Transplantation Immunology, Garvan Institute of Medical Research, Sydney, Australia.
Aims: Dendritic cells (DC) are the most potent antigen-presenting cell and are fundamental in the establishment of transplant tolerance. Targeting DC via the DC-SIGN receptor…
2016 American Transplant Congress
Effect of Complement Inhibition Therapy (Eculizumab) in Patients with C1q-Binding Donor-Specific Anti-HLA Antibodies: A Molecular Appraisal.
C. Lefaucheur,¹ L. Hidalgo,² J. Reeve,² D. Viglietti,¹ C. Gosset,¹ O. Aubert,³ C. Ulloa,³ C. Legendre,³ D. Glotz,¹ P. Halloran,² A. Loupy.³
¹Saint-Louis Hospital, Paris, France; ²University of Alberta, Edmonton, Canada; ³Necker Hospital, Paris, France.
Complement-binding anti-HLA DSA have demonstrated higher rejection rate and decreased allograft outcome. We investigated the effect of terminal complement inhibition (Eculizumab) in a cohort of…
2016 American Transplant Congress
Comparison of Pharmacokinetic and Clinical Outcomes of Tacrolimus Hexal^® with Prograf^® Based Regimen in De Novo Kidney Transplant Recipients: Results from the Randomized, SparTacus Study.
W. Arns,¹ A. Huppertz,¹ T. Rath,¹ S. Ziefle,¹ L. Rump,¹ A. Hansen,¹ D. Baeumer,² K. Budde,¹ L. Lehner,¹ T. Klein,¹ P. Schenker.¹
¹SparTacus Study Group, Cologne, Germany; ²Novartis Pharma GmbH, Nuernberg, Germany.
Background: There is very limited evidence on the pharmacokinetic (PK) and clinical outcomes, comparing a generic tacrolimus with the standard reference drug in transplant (Tx)…
2016 American Transplant Congress
Impact on Wound Healing Events After Early Conversion to Everolimus in De Novo Renal Transplant Recipients: 24-Month Results from the Randomized ELEVATE Study.
B. Nashan,¹ M. van der Giet,¹ H. Holdaas,¹ M. Zeier,¹ J. Pascual,¹ Y. Avihingsanon,¹ P. Lopez,² J. Aguilar-Sanchez,² J. Kochuparampil,² Z. Wang,³ J. Cruzado,¹ J. De Fijter.¹
¹ELEVATE Study Group, Hamburg, Germany; ²Novartis, Basel, Switzerland; ³Novartis Pharmaceutical Corporation, East Hanover.
BackgroundWound healing events (WHE) are probably the most common type of post-transplant (Tx) surgical complication. Due to its antiproliferative properties, mammalian target of rapamycin inhibitors…
2016 American Transplant Congress
Do We Need an Individually Tailored Immunosuppression Strategy for Living Donor Kidney Transplant Recipients with PreTransplant Donor Specific Antibodies? A Retrospective Analysis.
S. Bhutani,¹ A. Ponnusamy,² Q. Tak,¹ S. Shah,¹ J. Worthington,¹ A. Summers,¹ K. Poulton,¹ D. Van Dellen,¹ M. Morton,¹ M. Picton.¹
¹Department of Renal & Transplant Medicine, Manchester Royal Infirmary, Manchester, United Kingdom; ²Department of Renal Medicine, Royal Hospital Preston, Preston, United Kingdom.
Introduction:Pre-Transplant Microbead donor HLA specific antibody(DSA) positive but cell crossmatch negative transplants are considered to be at increased immunological risk. This study aimed to address…
2016 American Transplant Congress
Treatment of Late Antibody-Mediated Rejection: Observations from Clinical Practice.
G. Einecke,¹ J. Bräsen,² A. Schwarz,¹ H. Haller,¹ F. Njau.¹
¹Nephrology, Medical School of Hannover, Hannover, Germany; ²Pathology, Medical School of Hannover, Hannover, Germany.
Antibody-mediated rejection (AMR) is a major cause of late renal allograft failure. The benefit of treatment of chronic ABMR is unknown. Currently there is no…